Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Study of BAY 1895344 in Combination with Chemotherapy for Patients with Metastatic Gastrointestinal Cancer
Sponsor: ETCTN
Enrolling: Male and Female Patients
IRB Number: AAAT6928
U.S. Govt. ID: NCT04535401
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: What is the highest dose of BAY 1895344 and FOLFIRI chemotherapy (irinotecan, 5-fluorouracil, which is also known as 5-FU, and leucovorin) in combination that can be safely and tolerably taken in patients with advanced gastrointestinal cancer? This is the first time that these drugs will be tested together in humans. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your cancer. The usual approach is defined as care most people get for advanced gastrointestinal cancer. Cancers include esophageal cancer, colon and rectal cancer, and stomach cancer.
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have advanced or metastatic colon or gastroesophageal cancer and have progressed on at least one prior treatment? Yes No
Are you able to make extra visits to the clinic for treatment and assessments? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162